Patents by Inventor Timothy Charles Kiorpes

Timothy Charles Kiorpes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11904118
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: February 20, 2024
    Assignee: Micell Medtech Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20230381464
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Application
    Filed: August 8, 2023
    Publication date: November 30, 2023
    Applicant: MT Acquisition Holdings LLC
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Patent number: 10729819
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: August 4, 2020
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20200108232
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 9, 2020
    Applicant: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20190117851
    Abstract: A drug-eluting product is disclosed comprising an at least partially bioabsorbable element and an active pharmaceutical agent having a morphology, a solubility, and an average particle size which are selected so that the active pharmaceutical agent continues to dissolve during the biodegradation of the bioabsorbable element. The morphology is a crystalline, semi-crystalline or amorphous morphology, the solubility is less than 100 ?g/ml and the average particle size is grater that about 100 nm.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 25, 2019
    Applicant: Micell Technologies, Inc.
    Inventors: Timothy Charles Kiorpes, James B. McClain
  • Publication number: 20190046695
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 14, 2019
    Applicant: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Patent number: 10117972
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: November 6, 2018
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20180085498
    Abstract: A drug-eluting product is disclosed comprising an at least partially bioabsorbable element and an active pharmaceutical agent having a morphology, a solubility, and an average particle size which are selected so that the active pharmaceutical agent continues to dissolve during the biodegradation of the bioabsorbable element. The morphology is a crystalline, semi-crystalline or amorphous morphology, the solubility is less than 100 ?g/ml and the average particle size is grater that about 100 nm.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 29, 2018
    Applicant: Micell Technologies, Inc.
    Inventors: Timothy Charles Kiorpes, James B. McClain
  • Publication number: 20140350522
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Application
    Filed: July 12, 2012
    Publication date: November 27, 2014
    Applicant: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20130172853
    Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
    Type: Application
    Filed: July 15, 2011
    Publication date: July 4, 2013
    Applicant: MICELL TECHNOLOGIES, INC.
    Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
  • Publication number: 20120177742
    Abstract: Devices, coatings, and methods therefore comprise a medical device for delivering nanoparticles of an active agent to a treatment site. A coating on the medical device comprises active agent nanoparticles, which delivers coating to the treatment site and releases active agent nanoparticles into the treatment site over at least one day. A coating may comprise a polymer, a surfactant, and the nanoparticles. The coating may be prepared by forming a nanoemulsion. A coating may comprise encapsulated active agent nanoparticles which comprise active agent nanoparticles encapsulated in a polymer. The coating may have a positive surface charge. The coating may deliver active agent nanoparticles into the treatment site over at least about one day. The coating may be formed of a surfactant and nanoparticles mixture. The active agent nanoparticles may be deposited on the medical device using electrostatic capture.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 12, 2012
    Applicant: MICELL TECHNOLOGIES, INC.
    Inventors: James B. McCLAIN, Charles Douglas Taylor, Brett G. Zani, Timothy Charles Kiorpes
  • Patent number: 6800055
    Abstract: A low attenuation radioactive seed utilizing a core having a fluted or non-circular cross section is utilized for increasing the dose rate, decreasing the dwell times and improving the clinical outcomes by increasing the dose consistency throughout the treatment zone. The fluted or non-circular cross section core would increase the surface area for the deposition of the radioactive substance thereby increasing the therapeutic efficacy of the seed. In addition, the fluted or non-circular cross section may be designed in a manner to reduce photon emission attenuation by reducing the distance an inwardly directed photon would have to travel to traverse the core.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: October 5, 2004
    Assignee: Cordis Corporation
    Inventors: Howard Ira Amols, Timothy Charles Kiorpes, Benjamin David McDaniel, Michael Dennis O'Hara
  • Publication number: 20020123660
    Abstract: A low attenuation radioactive seed utilizing a core having a fluted or non-circular cross section is utilized for increasing the dose rate, decreasing the dwell times and improving the clinical outcomes by increasing the dose consistency throughout the treatment zone. The fluted or non-circular cross section core would increase the surface area for the deposition of the radioactive substance thereby increasing the therapeutic efficacy of the seed. In addition, the fluted or non-circular cross section may be designed in a manner to reduce photon emission attenuation by reducing the distance an inwardly directed photon would have to travel to traverse the core.
    Type: Application
    Filed: February 21, 2001
    Publication date: September 5, 2002
    Inventors: Howard Ira Amols`, Timothy Charles Kiorpes, Benjamin David McDaniel, Michael Dennis O'Hara